NisoldipineCAS# 63675-72-9 |
- Azelnidipine
Catalog No.:BCC4400
CAS No.:123524-52-7
- Verapamil HCl
Catalog No.:BCC4747
CAS No.:152-11-4
- Gabapentin HCl
Catalog No.:BCC4502
CAS No.:60142-95-2
- Manidipine
Catalog No.:BCC4404
CAS No.:89226-50-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 63675-72-9 | SDF | Download SDF |
| PubChem ID | 4499 | Appearance | Powder |
| Formula | C20H24N2O6 | M.Wt | 388.41 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (257.46 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 3-O-methyl 5-O-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | ||
| SMILES | CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC | ||
| Standard InChIKey | VKQFCGNPDRICFG-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Nisoldipine Dilution Calculator
Nisoldipine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5746 mL | 12.873 mL | 25.746 mL | 51.492 mL | 64.365 mL |
| 5 mM | 0.5149 mL | 2.5746 mL | 5.1492 mL | 10.2984 mL | 12.873 mL |
| 10 mM | 0.2575 mL | 1.2873 mL | 2.5746 mL | 5.1492 mL | 6.4365 mL |
| 50 mM | 0.0515 mL | 0.2575 mL | 0.5149 mL | 1.0298 mL | 1.2873 mL |
| 100 mM | 0.0257 mL | 0.1287 mL | 0.2575 mL | 0.5149 mL | 0.6436 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Nisoldipine is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM.
- H-D-Asp-Obzl
Catalog No.:BCC2895
CAS No.:6367-42-6
- H-Lys(Z)-OBzl.HCl
Catalog No.:BCC2987
CAS No.:6366-70-7
- Betaxolol HCl
Catalog No.:BCC4343
CAS No.:63659-19-8
- Z-D-Glu-OH
Catalog No.:BCC2775
CAS No.:63648-73-7
- Gamma-Methoxyisoeugenol
Catalog No.:BCN3999
CAS No.:63644-71-3
- 1,5-Bis(4-hydroxy-3-methoxyphenyl)penta-1,4-diene
Catalog No.:BCN1388
CAS No.:63644-68-8
- Coniferyl ferulate
Catalog No.:BCN8543
CAS No.:63644-62-2
- DADLE
Catalog No.:BCC6064
CAS No.:63631-40-3
- D-(+)-Maltose monohydrate
Catalog No.:BCN8423
CAS No.:6363-53-7
- 6-Hydroxydopamine hydrobromide
Catalog No.:BCC7403
CAS No.:636-00-0
- Terazosin
Catalog No.:BCC5162
CAS No.:63590-64-7
- Foscarnet Sodium
Catalog No.:BCC4782
CAS No.:63585-09-1
- Boc-D-Ser-OH
Catalog No.:BCC3447
CAS No.:6368-20-3
- Clofibrate
Catalog No.:BCC5308
CAS No.:637-07-0
- Pramoxine HCl
Catalog No.:BCC4705
CAS No.:637-58-1
- 2-(Dimethylamino)ethanesulfonic acid
Catalog No.:BCN1752
CAS No.:637-95-6
- (R)-Baclofen hydrochloride
Catalog No.:BCC4123
CAS No.:63701-55-3
- Z-Phenylalaninol
Catalog No.:BCC2716
CAS No.:6372-14-1
- Paspalinine
Catalog No.:BCN7386
CAS No.:63722-91-8
- Pseudoprotogracillin
Catalog No.:BCC8354
CAS No.:637349-03-2
- AEG 3482
Catalog No.:BCC8088
CAS No.:63735-71-7
- 3'-Amino-4'-methoxyacetanilide
Catalog No.:BCC8611
CAS No.:6375-47-9
- 6-Chloromelatonin
Catalog No.:BCC6651
CAS No.:63762-74-3
- 12alpha-Hydroxygrandiflorenic acid
Catalog No.:BCN4823
CAS No.:63768-17-2
Comparative evaluation of proliposomes and self micro-emulsifying drug delivery system for improved oral bioavailability of nisoldipine.[Pubmed:27041124]
Int J Pharm. 2016 May 30;505(1-2):79-88.
The objective of this study was to develop proliposomal formulation and self micro-emulsifying drug delivery system (SMEDDS) for a poorly bioavailable drug, Nisoldipine and to compare their in vivo pharmacokinetics. Proliposomes were prepared by thin film hydration method using different lipids such as Soy phosphatidylcholine (SPC), Hydrogenated Soy phosphatidylcholine (HSPC), Dimyristoylphosphatidylcholine (DMPC) and Dimyristoyl phosphatidylglycerol sodium (DMPG), Distearyl phosphatidylcholine (DSPC), and Cholesterol in various ratios. SMEDDS formulations were prepared using varying concentrations of Capmul MCM, Labrasol, Cremophor EL and Tween 80. Both proliposomes and SMEDDS were evaluated for particle size, zeta potential, in vitro drug release, in vitro permeability and in vivo pharmacokinetics. In vitro drug release was carried out in purified water using USP type II dissolution apparatus. In vitro drug permeation was studied using parallel artificial membrane permeation assay (PAMPA) and everted rat intestinal perfusion techniques. In vivo pharmacokinetic studies were conducted in male Sprague-Dawley rats. Among the different formulations, proliposomes with drug:DMPC:cholesterol in the ratio of 1:2:0.5 and SMEDDS with Capmul MCM (13.04% w/w), Labrasol (36.96% w/w), Cremophor EL (34.78% w/w) and Tween 80 (15.22% w/w) demonstrated the desired particle size and zeta potential. Enhanced drug release was observed with proliposomes and SMEDDS compared to pure Nisoldipine in purified water after 1h. Nisoldipine permeability across PAMPA and everted rat intestinal perfusion models was significantly higher with proliposomes and SMEDDS. Following single oral administration of proliposomes and SMEDDS, a relative bioavailability of 301.11% and 239.87% respectively, was achieved compared to pure Nisoldipine suspension.
Transdermal Delivery of Nisoldipine: Refinement of Vehicles.[Pubmed:26685495]
Int J Pharm Compd. 2015 Mar-Apr;19(2):152-60.
Nisoldipine is used for the treatment of hypertension and angina pectoris. However, it has very low bioavailabil-ty, which is attributed to extensive pre-systemic metabolism. In addition, nisol-ipine is highly potent (used at a low dose). Taking into consideration the fact that transdermal delivery avoids the pre-systemic metabolism and is only suit-ble for potent drugs, Nisoldipine can be considered as an excellent candidate for transdermal delivery. Accordingly, the purpose of this study was to optimize Nisoldipine transdermal delivery. That was achieved initially by investigating the effect of vehicles on skin penetration. The tested vehicles were ranked with respect to transdermal flux of Nisoldipine as isopropyl myristate > oleic acid > propylene glycol > water > polyethylene glycol 400. A combination of oleic acid with propylene glycol was synergistic with a ratio of 1:2 w/w being the best. These results were taken further to develop microemulsion systems using either oleic acid or isopropyl myristate as the oil phase. Both cases employed polyoxy-thylene sorbitan monooleate as a surfactant with propylene glycol being uti-ized as a cosurfactant in the case of oleic acid and ethanol in the case of isopropyl myristate. The developed microemulsions produced significant enhancement in Nisoldipine transdermal delivery with the flux being even greater than that obtained from the corresponding pure vehicles. This achieve-ent was recorded in optimum microemulsion formulations which contained a cosurfactant. The study provided stepwise optimization of a vehicle for trans-ermal delivery of Nisoldipine.
Optimization and development of Nisoldipine nano-bioenhancers by novel orthogonal array (L27 array).[Pubmed:26845477]
Int J Biol Macromol. 2016 May;86:556-61.
Our key objective was an attempt to apply a novel statistical method intended for designing, optimizing and developing Nisoldipine nano-bioenhancers using Taguchi (3 x 3=L27) design. This quality improvement orthogonal design array (L27) was used as a mathematical tool to find and study the response prediction of independent as well as significant variables (A=poly-concentration; B=bio-enhancer and C=ratio of organic medium). The array orthogonal (3 x 3=L27) at each level/spaces has been studied with respect to responses changeable (dependent factors); entrapment enhancement (X; evaluated using particle size; Y). All through experimentally performed runs, the results showed independent variables effect individually or simultaneously on changeable (dependent) variables. It also predicted significant variable via its "better to best" optimized spaces (independent level) and would be considered as novel statistically advanced oral drug delivery vehicle for anti-hypertensive agents.
Investigating the role of nisoldipine in foot-shock-induced post-traumatic stress disorder in mice.[Pubmed:26662718]
Fundam Clin Pharmacol. 2016 Apr;30(2):128-36.
This study was designed to investigate the effectiveness of Nisoldipine, an L-type voltage-sensitive calcium channel blocker, to ameliorate anxiety and fear response in a mouse model of post-traumatic stress disorder (PTSD). Acute trauma was induced in Swiss albino mice in a 2-day electric foot-shock paradigm consisting of 15 intermittent foot-shocks of 0.8 mA intensity, 10-s duration and 10-s intershock interval, during 5 min, followed by 3 weekly situational reminders, that is, once per week in the same context on three successive weeks. PTSD-induced behavioral changes were assessed using actophotometer, open-field, social interaction test, and freezing behavior. Biochemically, the serum corticosterone levels were estimated. Electric foot-shock and situational reminders produced behavioral alterations and decreased corticosterone levels, assessed on the 21st day following the traumatic event. Administration of sertraline (Ser 15 mg/kg), a selective serotonin reuptake inhibitor (SSRI) and Nisoldipine (20 and 40 mg/kg), significantly attenuated the foot-shock-trauma-induced behavioral changes along with normalization of the corticosterone levels. It may be concluded that Nisoldipine produces beneficial effects in re-establishing behavioral alterations, which may be due to normalization of reduced corticosterone levels in PTSD in mice.
